[Clinical pharmacy in a bone marrow and cellular therapy transplantation ward-which methods to put in place: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Pharmacie clinique en unité de greffe de moelle osseuse et thérapie cellulaire – quelles activités mettre en place ? Recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 04 05 2018
accepted: 09 07 2018
pubmed: 21 11 2018
medline: 15 2 2019
entrez: 21 11 2018
Statut: ppublish

Résumé

Since, several years the integration of a clinical pharmacist in medical units led to improve the patients' care in France. In the frame of stem cell engraftment, patients belong to a particularly complex population, notably due to pediatric patients or because the age to engraft adult patients is higher. Moreover, because of many reasons, such as numerous medications intake or long-term immunosuppression, these patients are very fragile and at risk of complications. Since the 6th edition, the JACIE standard gives a definition of the role of clinical pharmacist with its competence area and its place in the medical ward. In the aim to standardize the procedures of stem cell transplantation, this 8th congress of the francophone Society of bone marrow transplantation and cellular therapy has proposed a collective proposition of the place and the missions of clinical pharmacists in the transplant units.

Identifiants

pubmed: 30454986
pii: S0007-4551(18)30284-4
doi: 10.1016/j.bulcan.2018.07.020
pii:
doi:

Types de publication

Consensus Development Conference Journal Article Practice Guideline Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

S59-S70

Informations de copyright

Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Edouard Forcade (E)

CHU Bordeaux, service hématologie clinique et thérapie cellulaire, 33000 Bordeaux, France.

Agnès Bonnin (A)

AP-HP, hôpital Saint-Antoine, service hématologie clinique et thérapie cellulaire, 75012 Paris, France.

Judith Desoutter (J)

CHU Amiens, service hématologie clinique et thérapie cellulaire, 80054 Amiens, France.

Francisca Nacimento (F)

CHU Réunion site, banque de cellules et tissus, 97448 Saint-Pierre, France.

Isabelle Roch-Torreilles (I)

CHU Montpellier, pharmacie site Saint-Éloi, 34295 Montpellier, France.

Flore Vigneron (F)

CHU Montpellier, pharmacie site Saint-Éloi, 34295 Montpellier, France.

Jean-Michel Boiron (JM)

Université de Bordeaux, hématologie-transfusion, UFR médecine, Inserm U1034, 1, avenue de Magellan, 33600 Pessac, France.

Ibrahim Yakoub-Agha (I)

CHU Lille, maladies du sang, unité d'allogreffe de CSH, 59000 Lille, France; Université Lille, U995 - LIRIC, Lille Inflammation Research International Center, 59000 Lille, France.

Nicolas Simon (N)

Université Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes injectables et les technologies associées, 59000 Lille, France; CHU Lille, Institut de Pharmacie, 59000 Lille, France. Electronic address: nicolas.simon@univ-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH